IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-01293729.html
   My bibliography  Save this paper

Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies

Author

Listed:
  • J. Beauté

    (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP))

  • Pierre Lévy

    (LEDa - Laboratoire d'Economie de Dauphine - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres)

  • V. Millet
  • M. Debré
  • Y. Dudoit

    (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP))

  • L. Le Mignot

    (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP))

  • A. Tajahmady
  • C. Thomas
  • F. Suarez

    (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP))

  • I. Pellier
  • O. Hermine

    (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP))

  • N. Aladjidi
  • N. Mahlaoui

    (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP))

  • A. Fischer

    (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP))

Abstract

Lifelong immunoglobulin replacement is the standard, expensive therapy for severe primary antibody deficiencies. This treatment can be administrated either by intravenous immunoglobulin (IVIG) or subcutaneous infusions (SCIG) and delivered at home or in an out-patient setting. This study aims to determine whether SCIG is cost-effective compared with IVIG from a French social insurance perspective. Because both methods of administration provide similar efficacies, a cost-minimization analysis was performed. First, costs were calculated through a simulation testing different hypothesis on costs drivers. Secondly, costs were estimated on the basis of field data collected by a questionnaire completed by a population of patients suffering from agammaglobulinaemia and hyper-immunoglobulin (Ig)M syndrome. Patients' satisfaction was also documented. Results of the simulation showed that direct medical costs ranged from €19 484 for home-based IVIG to €25 583 for hospital-based IVIG, with home-based SCIG in between at €24 952 per year. Estimations made from field data were found to be different, with significantly higher costs for IVIG. This result was explained mainly by a higher immunoglobulin mean dose prescribed for IVIG. While the theoretical model showed very little difference between SCIG and hospital-based IVIG costs, SCIG appears to be 25% less expensive with field data because of lower doses used in SCIG patients. The reality of the dose difference between both routes of administration needs to be confirmed by further and more specific studies.

Suggested Citation

  • J. Beauté & Pierre Lévy & V. Millet & M. Debré & Y. Dudoit & L. Le Mignot & A. Tajahmady & C. Thomas & F. Suarez & I. Pellier & O. Hermine & N. Aladjidi & N. Mahlaoui & A. Fischer, 2010. "Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies," Post-Print hal-01293729, HAL.
    • Handle: RePEc:hal:journl:hal-01293729
    DOI: 10.1111/j.1365-2249.2009.04079.x
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Clémence Perraudin & Aline Bourdin & Alex Vicino & Thierry Kuntzer & Olivier Bugnon & Jérôme Berger, 2020. "Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis," PLOS ONE, Public Library of Science, vol. 15(11), pages 1-12, November.
    2. Rajiv Mallick & Rashad Carlton & Joris Stiphout, 2023. "A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States," PharmacoEconomics - Open, Springer, vol. 7(2), pages 243-255, March.
    3. Laia Alsina & J. Bruno Montoro & Pedro Moral Moral & Olaf Neth & Marta Ortiz Pica & Silvia Sánchez-Ramón & María Presa & Itziar Oyagüez & Miguel Ángel Casado & Luis Ignacio González-Granado, 2022. "Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(3), pages 551-558, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-01293729. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.